NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

APRE

Aprea Therapeutics Inc

Jul 03 • 04:00PM ET

1.74

Dollar change +0.04
Percentage change 2.35	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK PFE GILD VRTX AMGN BIIB REGN NBIX INCY

| Held by: VTI VXF DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.36	Insider Own	12.88%	Shs Outstand	5.51M	Perf Week	-0.71%
Market Cap	9.62M	Forward P/E	-	EPS next Y	-1.46	Insider Trans	0.78%	Shs Float	4.82M	Perf Month	-4.08%
Enterprise Value	-8.35M	PEG	-	EPS next Q	-0.71	Inst Own	35.25%	Short Float	1.51%	Perf Quarter	-6.95%
Income	-14.08M	P/S	7.52	EPS this Y	30.22%	Inst Trans	-2.31%	Short Ratio	1.98	Perf Half Y	-50.00%
Sales	1.28M	P/B	0.62	EPS next Y	10.97%	ROA	-52.72%	Short Interest	0.07M	Perf YTD	-47.11%
Book/sh	2.82	P/C	0.50	EPS next 5Y	36.56%	ROE	-59.80%	52W High	5.01 -65.27%	Perf Year	-56.82%
Cash/sh	3.49	P/FCF	-	EPS past 3/5Y	59.30% 52.12%	ROIC	-83.51%	52W Low	1.41 23.23%	Perf 3Y	-89.58%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	98.32%	Volatility	6.89% 9.07%	Perf 5Y	-99.78%
Dividend TTM	-	EV/Sales	-6.52	EPS Y/Y TTM	28.85%	Oper. Margin	-1187.69%	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.90	Sales Y/Y TTM	33.27%	Profit Margin	-1096.27%	RSI (14)	50.19	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.90	EPS Q/Q	1.97%	SMA20	-0.70%	Beta	1.29	Target Price	10.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-57.31%	SMA50	0.75%	Rel Volume	0.25	Prev Close	1.70
Employees	8	LT Debt/Eq	0.00	Earnings	May 14 BMO	SMA200	-36.14%	Avg Volume	36.77K	Price	1.74
IPO	Oct 03, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-0.87% -	Trades		Volume	9,119	Change	2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy	$37
Sep-29-20	Resumed	JP Morgan	Neutral	$25
Jun-22-20	Initiated	H.C. Wainwright	Neutral	$30
Apr-21-20	Initiated	Robert W. Baird	Outperform	$45
Oct-28-19	Initiated	RBC Capital Mkts	Outperform	$33
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight	$23
Oct-28-19	Initiated	JP Morgan	Neutral	$23

Jun-25-25 09:00AM	Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center (GlobeNewswire) +10.09%
May-14-25 08:00AM	Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update (GlobeNewswire)
May-06-25 04:01PM	Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Apr-17-25 07:00AM	Adicet Bio Appoints Michael Grissinger to the Board of Directors (Business Wire)
Apr-01-25 08:49AM	Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial (Clinical Trials Arena) -5.88%
08:30AM	Loading…
Mar-31-25 08:30AM	Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial (GlobeNewswire)
Mar-25-25 08:30AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-11-25 08:30AM	Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) (GlobeNewswire) +9.87%
Feb-06-25 08:16AM	Aprea Therapeutics provides update on existing patent portfolio (TipRanks)
Feb-05-25 08:00AM	Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics (GlobeNewswire)
Dec-11-24 08:30AM	Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward (GlobeNewswire)
Nov-13-24 09:55AM	Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-07-24 09:20AM	Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 08:40AM	Aprea Therapeutics presents preliminary results on APR-1051 (TipRanks)
08:30AM	Loading…
Oct-23-24 08:30AM	Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire) -6.70%
Oct-14-24 08:30AM	Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit (GlobeNewswire)
Oct-10-24 07:03PM	Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc (GuruFocus.com)
08:30AM	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire)
Oct-09-24 08:30AM	Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development (GlobeNewswire)
Sep-25-24 08:00AM	Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) +7.19%
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
Sep-12-24 08:30AM	Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 (GlobeNewswire) +6.21%
Sep-09-24 05:15PM	UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 08:30AM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 09:45AM	Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
08:00AM	Loading…
Jun-21-24 08:00AM	Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 (GlobeNewswire)
Jun-17-24 08:30AM	Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 (GlobeNewswire)
May-28-24 08:45AM	Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial (GlobeNewswire)
May-14-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +5.37%
08:30AM	Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-13-24 04:01PM	Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-02-24 09:15AM	Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-24 12:00PM	Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 (GlobeNewswire)
Mar-26-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
07:45AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-11-24 08:30AM	Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million (GlobeNewswire) -5.05%
08:29AM	Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers (GlobeNewswire)
Mar-05-24 04:45PM	Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-06-24 08:01AM	Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor (GlobeNewswire) +11.97%
Jan-30-24 08:00AM	Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 (GlobeNewswire)
Jan-04-24 04:05PM	Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 (GlobeNewswire)
Nov-09-23 04:05PM	Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -5.19%
Oct-24-23 08:00AM	Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways (GlobeNewswire)
Oct-16-23 08:30AM	Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio (GlobeNewswire)
Sep-19-23 08:00AM	Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-11-23 08:00AM	Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors (GlobeNewswire)
Sep-06-23 04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 07:30AM	Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman (GlobeNewswire)
Aug-10-23 07:30AM	Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Jun-14-23 08:00AM	Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference (GlobeNewswire)
May-30-23 08:30AM	Aprea Therapeutics to Present at BIO International Convention (GlobeNewswire) +11.76%
May-15-23 04:05PM	Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire) -7.34% +6.20%
May-08-23 08:00AM	Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors (GlobeNewswire)
Apr-24-23 09:55AM	Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now (Zacks)
Apr-04-23 12:00PM	All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy (Zacks) -5.01%
Mar-30-23 04:05PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Mar-16-23 08:00AM	Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.26%
Mar-01-23 04:05PM	Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-27-23 04:05PM	Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Feb-22-23 08:41PM	Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.97%
04:05PM	Aprea Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-15-23 08:00AM	Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI) (GlobeNewswire)
Feb-13-23 07:00AM	Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split (GlobeNewswire)
Jan-30-23 08:00AM	Aprea Therapeutics Appoints John Hamill as Chief Financial Officer (GlobeNewswire)
Jan-19-23 08:00AM	Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit (GlobeNewswire) -7.57%
Jan-12-23 09:56AM	Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies (Zacks)
Jan-11-23 08:00AM	Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors (GlobeNewswire) +11.99%
Nov-09-22 04:15PM	Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire) -10.88%
Sep-22-22 06:00PM	Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series (GlobeNewswire) -7.14%
Sep-08-22 08:00AM	Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-11-22 04:15PM	Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Aug-02-22 08:00AM	Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
May-19-22 06:30AM	The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal (American City Business Journals)
May-16-22 09:21AM	Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results (GlobeNewswire) -19.09%
Mar-15-22 04:15PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire) +5.45% +14.37%
Mar-02-22 04:41AM	Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-14-22 10:00AM	Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-06-22 08:00AM	Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 (GlobeNewswire)
Dec-14-21 08:00AM	Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -10.05%
Dec-13-21 08:00AM	Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -10.85%
Dec-10-21 10:30AM	Aprea (APRE) Reports FDA Removal of Clinical Hold on Study (Zacks)
Dec-09-21 12:30PM	FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies (Benzinga)
08:00AM	Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies (GlobeNewswire)
Nov-08-21 04:15PM	Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Nov-04-21 04:15PM	Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting (GlobeNewswire)
Sep-21-21 08:39AM	Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO (Benzinga)
07:01AM	18 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
Sep-20-21 04:15PM	Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021 (GlobeNewswire)
08:42AM	Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock? (Zacks)
Sep-14-21 08:00AM	Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021 (GlobeNewswire)
Sep-03-21 07:21AM	Are Institutions Heavily Invested In Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Shares? (Simply Wall St.)
Aug-12-21 04:15PM	Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire) -9.65%
06:00AM	Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program (GlobeNewswire)
Aug-05-21 05:00PM	Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs (GlobeNewswire)

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gilad Oren	President/CEO	Apr 03 '25	Buy	1.84	5,500	10,110	345,620	Apr 04 07:30 AM
Duey Marc	Director	Oct 18 '24	Sale	4.58	6,462	29,583	233,651	Oct 25 05:42 PM
Gilad Oren	President/CEO	Oct 23 '24	Buy	3.92	500	1,958	333,395	Oct 24 08:30 AM
Duey Marc	Director	Oct 16 '24	Buy	4.39	30,000	131,700	240,113	Oct 17 08:30 AM
Gilad Oren	President/CEO	Oct 15 '24	Buy	2.90	250	725	332,895	Oct 16 08:31 AM
Duey Marc	Director	Oct 14 '24	Buy	2.58	190	490	210,113	Oct 16 08:30 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Oct 11 '24	Buy	2.46	50	123	19,368	Oct 16 08:30 AM
Seizinger Bernd R.	Director	Oct 11 '24	Buy	2.68	10,000	26,800	44,730	Oct 15 08:31 AM
Gilad Oren	President/CEO	Oct 14 '24	Buy	2.59	1,000	2,590	332,645	Oct 15 08:31 AM
Gilad Oren	President/CEO	Oct 10 '24	Buy	2.54	150	381	331,645	Oct 15 08:31 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Oct 10 '24	Buy	2.61	450	1,174	19,318	Oct 15 08:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APRE

Aprea Therapeutics Inc

Upgrade your FINVIZ experience